CN112891358A - Bcl-2抑制剂的应用及治疗衰老相关皮肤病的药物组合物 - Google Patents
Bcl-2抑制剂的应用及治疗衰老相关皮肤病的药物组合物 Download PDFInfo
- Publication number
- CN112891358A CN112891358A CN202110074555.0A CN202110074555A CN112891358A CN 112891358 A CN112891358 A CN 112891358A CN 202110074555 A CN202110074555 A CN 202110074555A CN 112891358 A CN112891358 A CN 112891358A
- Authority
- CN
- China
- Prior art keywords
- bcl
- inhibitor
- aging
- solvent
- psoriasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title claims abstract description 64
- 229940123711 Bcl2 inhibitor Drugs 0.000 title claims abstract description 64
- 230000032683 aging Effects 0.000 title claims abstract description 55
- 208000017520 skin disease Diseases 0.000 title claims abstract description 52
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 23
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 76
- 239000003814 drug Substances 0.000 claims abstract description 34
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 23
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 claims description 108
- 238000011282 treatment Methods 0.000 claims description 71
- 238000002347 injection Methods 0.000 claims description 65
- 239000007924 injection Substances 0.000 claims description 65
- 239000007929 subcutaneous injection Substances 0.000 claims description 46
- 238000010254 subcutaneous injection Methods 0.000 claims description 46
- 238000002360 preparation method Methods 0.000 claims description 41
- 239000002904 solvent Substances 0.000 claims description 38
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 32
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 31
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 23
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- 239000003961 penetration enhancing agent Substances 0.000 claims description 16
- 239000008055 phosphate buffer solution Substances 0.000 claims description 16
- 239000011159 matrix material Substances 0.000 claims description 14
- -1 patch Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000003755 preservative agent Substances 0.000 claims description 10
- 230000002335 preservative effect Effects 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 8
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- 239000007853 buffer solution Substances 0.000 claims description 8
- 229960001631 carbomer Drugs 0.000 claims description 8
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 8
- 239000006210 lotion Substances 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 8
- 201000004624 Dermatitis Diseases 0.000 claims description 7
- 230000006909 anti-apoptosis Effects 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 230000009885 systemic effect Effects 0.000 claims description 7
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 239000003906 humectant Substances 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 239000007972 injectable composition Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 4
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 4
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 4
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 claims description 4
- 239000005642 Oleic acid Substances 0.000 claims description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 4
- 208000003251 Pruritus Diseases 0.000 claims description 4
- 239000008351 acetate buffer Substances 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 229960002233 benzalkonium bromide Drugs 0.000 claims description 4
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 claims description 4
- 229940116229 borneol Drugs 0.000 claims description 4
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 4
- 229960004926 chlorobutanol Drugs 0.000 claims description 4
- 239000007979 citrate buffer Substances 0.000 claims description 4
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 4
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 4
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 4
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 4
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 4
- 239000007888 film coating Substances 0.000 claims description 4
- 238000009501 film coating Methods 0.000 claims description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 4
- 229940041616 menthol Drugs 0.000 claims description 4
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 claims description 4
- 229950004847 navitoclax Drugs 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000006072 paste Substances 0.000 claims description 4
- 239000011505 plaster Substances 0.000 claims description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 4
- 239000004299 sodium benzoate Substances 0.000 claims description 4
- 235000010234 sodium benzoate Nutrition 0.000 claims description 4
- 229960003885 sodium benzoate Drugs 0.000 claims description 4
- 239000004334 sorbic acid Substances 0.000 claims description 4
- 235000010199 sorbic acid Nutrition 0.000 claims description 4
- 229940075582 sorbic acid Drugs 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000000341 volatile oil Substances 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 206010013886 Dysaesthesia Diseases 0.000 claims description 3
- 208000010201 Exanthema Diseases 0.000 claims description 3
- 206010023330 Keloid scar Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000007256 Nevus Diseases 0.000 claims description 3
- 206010034277 Pemphigoid Diseases 0.000 claims description 3
- 241000721454 Pemphigus Species 0.000 claims description 3
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 208000019748 bullous skin disease Diseases 0.000 claims description 3
- 230000002327 eosinophilic effect Effects 0.000 claims description 3
- 201000005884 exanthem Diseases 0.000 claims description 3
- 208000000069 hyperpigmentation Diseases 0.000 claims description 3
- 230000003810 hyperpigmentation Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000007803 itching Effects 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 230000003448 neutrophilic effect Effects 0.000 claims description 3
- 208000035824 paresthesia Diseases 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 206010037844 rash Diseases 0.000 claims description 3
- 230000001373 regressive effect Effects 0.000 claims description 3
- 210000001626 skin fibroblast Anatomy 0.000 claims description 3
- 238000002627 tracheal intubation Methods 0.000 claims description 3
- 230000037303 wrinkles Effects 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 206010015278 Erythrodermic psoriasis Diseases 0.000 claims description 2
- 101000656751 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S24e Proteins 0.000 claims description 2
- 239000005639 Lauric acid Substances 0.000 claims description 2
- 206010051246 Photodermatosis Diseases 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 206010037575 Pustular psoriasis Diseases 0.000 claims description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 125000003158 alcohol group Chemical group 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 229940045110 chitosan Drugs 0.000 claims description 2
- 208000037765 diseases and disorders Diseases 0.000 claims description 2
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 claims description 2
- 230000002431 foraging effect Effects 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 229960002900 methylcellulose Drugs 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- 230000008845 photoaging Effects 0.000 claims description 2
- 229920001993 poloxamer 188 Polymers 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 2
- 230000000284 resting effect Effects 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 claims 1
- 206010040954 Skin wrinkling Diseases 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 230000036211 photosensitivity Effects 0.000 claims 1
- 239000007928 intraperitoneal injection Substances 0.000 abstract description 43
- 230000014509 gene expression Effects 0.000 abstract description 28
- 238000013309 psoriasis mouse model Methods 0.000 abstract description 27
- 229960002751 imiquimod Drugs 0.000 abstract description 22
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 abstract description 22
- 108020004999 messenger RNA Proteins 0.000 abstract description 20
- 230000037380 skin damage Effects 0.000 abstract description 18
- 238000000034 method Methods 0.000 abstract description 16
- 230000002757 inflammatory effect Effects 0.000 abstract description 13
- 230000008595 infiltration Effects 0.000 abstract description 12
- 238000001764 infiltration Methods 0.000 abstract description 12
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 11
- 208000024891 symptom Diseases 0.000 abstract description 11
- 230000002500 effect on skin Effects 0.000 abstract description 9
- 206010015150 Erythema Diseases 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 7
- 108050003558 Interleukin-17 Proteins 0.000 abstract description 6
- 102000013691 Interleukin-17 Human genes 0.000 abstract description 6
- 102100030703 Interleukin-22 Human genes 0.000 abstract description 6
- 108010074109 interleukin-22 Proteins 0.000 abstract description 6
- 102100037850 Interferon gamma Human genes 0.000 abstract description 5
- 108010074328 Interferon-gamma Proteins 0.000 abstract description 5
- 102000013264 Interleukin-23 Human genes 0.000 abstract description 5
- 108010065637 Interleukin-23 Proteins 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 65
- 210000003491 skin Anatomy 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 35
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 31
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 26
- 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 26
- 101000800539 Mus musculus Translationally-controlled tumor protein Proteins 0.000 description 26
- 101000781972 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein wos2 Proteins 0.000 description 26
- 101001009610 Toxoplasma gondii Dense granule protein 5 Proteins 0.000 description 26
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 26
- 238000000465 moulding Methods 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 238000010186 staining Methods 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 206010040882 skin lesion Diseases 0.000 description 16
- 231100000444 skin lesion Toxicity 0.000 description 16
- 210000001165 lymph node Anatomy 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 14
- 230000001575 pathological effect Effects 0.000 description 13
- 210000000170 cell membrane Anatomy 0.000 description 9
- 210000004207 dermis Anatomy 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000002159 abnormal effect Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 210000004969 inflammatory cell Anatomy 0.000 description 8
- 210000003289 regulatory T cell Anatomy 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 108091012583 BCL2 Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 210000004430 acanthocyte Anatomy 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 7
- 239000012188 paraffin wax Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000011529 RT qPCR Methods 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000009759 skin aging Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000010586 diagram Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000007910 systemic administration Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 4
- 210000000447 Th1 cell Anatomy 0.000 description 4
- 210000000068 Th17 cell Anatomy 0.000 description 4
- 210000004241 Th2 cell Anatomy 0.000 description 4
- 210000000270 basal cell Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 210000003855 cell nucleus Anatomy 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000005775 Parakeratosis Diseases 0.000 description 3
- 206010040867 Skin hypertrophy Diseases 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000001969 hypertrophic effect Effects 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010000349 Acanthosis Diseases 0.000 description 2
- 101000697844 Arabidopsis thaliana Thiosulfate sulfurtransferase 16, chloroplastic Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 102100033461 Interleukin-17A Human genes 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000633 nuclear envelope Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 230000037075 skin appearance Effects 0.000 description 2
- 210000000498 stratum granulosum Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 101710200158 DNA packaging protein Proteins 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 101710188689 Small, acid-soluble spore protein 1 Proteins 0.000 description 1
- 101710188693 Small, acid-soluble spore protein 2 Proteins 0.000 description 1
- 101710166422 Small, acid-soluble spore protein A Proteins 0.000 description 1
- 101710166404 Small, acid-soluble spore protein C Proteins 0.000 description 1
- 101710174019 Small, acid-soluble spore protein C1 Proteins 0.000 description 1
- 101710174017 Small, acid-soluble spore protein C2 Proteins 0.000 description 1
- 101710174574 Small, acid-soluble spore protein gamma-type Proteins 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004706 cardiovascular dysfunction Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940042129 topical gel Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2021/124587 WO2022105511A1 (zh) | 2020-11-19 | 2021-10-19 | Bcl-2抑制剂的应用及治疗衰老相关皮肤病的药物组合物 |
EP21867879.5A EP4029504A4 (en) | 2020-11-19 | 2021-10-19 | USE OF BCL-2 INHIBITOR AND PHARMACEUTICAL COMPOSITION FOR TREATING AGE-RELATED SKIN DISEASE |
JP2022516727A JP7378596B2 (ja) | 2020-11-19 | 2021-10-19 | Bcl-2阻害剤の適用及び老化関連皮膚病を治療するための薬物組成物 |
US17/755,182 US20230398133A1 (en) | 2020-11-19 | 2021-10-19 | Use of b-cell lymphoma 2 (bcl-2) inhibitor and pharmaceutical composition for treating cellular senescence-related skin diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011301947 | 2020-11-19 | ||
CN2020113019478 | 2020-11-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112891358A true CN112891358A (zh) | 2021-06-04 |
CN112891358B CN112891358B (zh) | 2023-05-12 |
Family
ID=76116520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110074555.0A Active CN112891358B (zh) | 2020-11-19 | 2021-01-20 | Bcl-2抑制剂的应用及治疗衰老相关皮肤病的药物组合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230398133A1 (zh) |
EP (1) | EP4029504A4 (zh) |
JP (1) | JP7378596B2 (zh) |
CN (1) | CN112891358B (zh) |
WO (1) | WO2022105511A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113975249A (zh) * | 2021-10-14 | 2022-01-28 | 中山大学·深圳 | Tris-BNP纳米颗粒的制备及其在皮肤疾病治疗中的应用 |
WO2022105511A1 (zh) * | 2020-11-19 | 2022-05-27 | 苏州正永生物医药有限公司 | Bcl-2抑制剂的应用及治疗衰老相关皮肤病的药物组合物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106163557A (zh) * | 2014-01-28 | 2016-11-23 | 巴克老龄化研究所 | 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物 |
CN106456699A (zh) * | 2014-05-05 | 2017-02-22 | 阿肯色大学评议会 | 作为抗老化剂抑制抗凋亡的Bcl‑2蛋白的组合物和方法 |
US20180193458A1 (en) * | 2015-07-08 | 2018-07-12 | Unity Biotechnology, Inc. | Compositions and methods for treating senescence-associated diseases and disorders |
CN110678751A (zh) * | 2017-03-09 | 2020-01-10 | 克利拉生物技术有限公司 | 针对细胞衰老的生物标志物 |
CN110678187A (zh) * | 2017-05-26 | 2020-01-10 | 英国研究与创新公司 | 衰老细胞清除化合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106074575A (zh) * | 2015-04-27 | 2016-11-09 | 陈骏英 | 一种用于治疗食管癌的药物及使用方法 |
CN106074574A (zh) * | 2015-04-27 | 2016-11-09 | 陈骏英 | 一种用于治疗食管癌的药物及使用方法 |
US20200371122A1 (en) * | 2017-10-06 | 2020-11-26 | Buck Institute For Research On Aging | Biomarker for senescent cells |
CN112891358B (zh) * | 2020-11-19 | 2023-05-12 | 苏州正永生物医药有限公司 | Bcl-2抑制剂的应用及治疗衰老相关皮肤病的药物组合物 |
-
2021
- 2021-01-20 CN CN202110074555.0A patent/CN112891358B/zh active Active
- 2021-10-19 WO PCT/CN2021/124587 patent/WO2022105511A1/zh unknown
- 2021-10-19 US US17/755,182 patent/US20230398133A1/en active Pending
- 2021-10-19 EP EP21867879.5A patent/EP4029504A4/en active Pending
- 2021-10-19 JP JP2022516727A patent/JP7378596B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106163557A (zh) * | 2014-01-28 | 2016-11-23 | 巴克老龄化研究所 | 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物 |
CN106456699A (zh) * | 2014-05-05 | 2017-02-22 | 阿肯色大学评议会 | 作为抗老化剂抑制抗凋亡的Bcl‑2蛋白的组合物和方法 |
US20180193458A1 (en) * | 2015-07-08 | 2018-07-12 | Unity Biotechnology, Inc. | Compositions and methods for treating senescence-associated diseases and disorders |
CN110678751A (zh) * | 2017-03-09 | 2020-01-10 | 克利拉生物技术有限公司 | 针对细胞衰老的生物标志物 |
CN110678187A (zh) * | 2017-05-26 | 2020-01-10 | 英国研究与创新公司 | 衰老细胞清除化合物 |
Non-Patent Citations (1)
Title |
---|
MATS KARLBERG等: ""The BH3-Mimetic ABT-737 Induces Mast Cell Apoptosis In Vitro and In Vivo: Potential for Therapeutics"", 《J IMMUNOL》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022105511A1 (zh) * | 2020-11-19 | 2022-05-27 | 苏州正永生物医药有限公司 | Bcl-2抑制剂的应用及治疗衰老相关皮肤病的药物组合物 |
CN113975249A (zh) * | 2021-10-14 | 2022-01-28 | 中山大学·深圳 | Tris-BNP纳米颗粒的制备及其在皮肤疾病治疗中的应用 |
Also Published As
Publication number | Publication date |
---|---|
JP7378596B2 (ja) | 2023-11-13 |
JP2023505923A (ja) | 2023-02-14 |
CN112891358B (zh) | 2023-05-12 |
EP4029504A1 (en) | 2022-07-20 |
EP4029504A4 (en) | 2022-11-02 |
WO2022105511A1 (zh) | 2022-05-27 |
US20230398133A1 (en) | 2023-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018295944B2 (en) | Topical formulations comprising montelukast and combinations with mussel adhesive proteins | |
US11059859B2 (en) | Anti-inflammatory use of peptide | |
Gao et al. | Hyaluronan oligosaccharides promote excisional wound healing through enhanced angiogenesis | |
JP7378596B2 (ja) | Bcl-2阻害剤の適用及び老化関連皮膚病を治療するための薬物組成物 | |
WO2019228307A1 (en) | New pharmaceutical use | |
CN104394883B (zh) | 炎性皮肤病症的治疗 | |
WO2021175186A1 (zh) | 小分子短肽在制备治疗痤疮的产品中的应用 | |
Ghufran et al. | Curcumin preconditioned human adipose derived stem cells co-transplanted with platelet rich plasma improve wound healing in diabetic rats | |
CN106456542A (zh) | 用于局部递送的适体 | |
Fan et al. | Celastrol relieves myocardial infarction-induced cardiac fibrosis by inhibiting NLRP3 inflammasomes in rats | |
CN116425836A (zh) | A+多肽/蛋白质及其应用 | |
CN113929750B (zh) | 一种具有修复皮肤屏障功能的多肽及其应用 | |
CN113876956B (zh) | Pcsk9抑制剂在制备促进皮肤色素生成产品中的应用 | |
WO2024027786A1 (zh) | 痤疮丙酸杆菌、其应用、组合物和药物 | |
WO2024001838A1 (zh) | 具有促进毛发生长的人体共生菌及其应用 | |
CN102416026A (zh) | 纳米级银杏叶提取物外用制剂的制备方法 | |
Zhai et al. | Cold atmospheric plasma for chronic kidney disease–related skin disorders | |
CN117860670A (zh) | 一种千层纸素外用制剂及其在银屑病治疗上的应用 | |
US20230346773A1 (en) | Use of pcsk9 inhibitor in preparation of product for treating multiple diseases | |
CN113995763A (zh) | 磷脂酰乙醇胺作为活性成分在制备银屑病治疗药物中的应用、银屑病治疗药物及其制备方法 | |
CN102071189B (zh) | 一种治疗银屑病的小干扰rna | |
Yazawa | studieson Eiizymes in the Lesions of Leprosy* ゜ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20211105 Address after: Room 405, building 11, Northwest District, Suzhou nano City, No. 99, Jinjihu Avenue, Suzhou Industrial Park, Suzhou City, Jiangsu Province, 215123 Applicant after: SUZHOU EON BIOPHARMACEUTICAL CO.,LTD. Applicant after: Nanchang antishensi biomedical Co.,Ltd. Address before: Room 405, building 11, Northwest District, Suzhou nano City, No. 99, Jinjihu Avenue, Suzhou Industrial Park, Suzhou City, Jiangsu Province, 215123 Applicant before: SUZHOU EON BIOPHARMACEUTICAL CO.,LTD. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230616 Address after: 330096 Room b02, Floor 4, Building 15, No. 269, Aixihu North Road, Nanchang High tech Industrial Development Zone, Nanchang City, Jiangxi Province Patentee after: Nanchang antishensi biomedical Co.,Ltd. Address before: Room 405, building 11, Northwest District, Suzhou nano City, No. 99, Jinjihu Avenue, Suzhou Industrial Park, Suzhou City, Jiangsu Province, 215123 Patentee before: SUZHOU EON BIOPHARMACEUTICAL CO.,LTD. Patentee before: Nanchang antishensi biomedical Co.,Ltd. |